{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:11:30Z","timestamp":1790734290418,"version":"4.1.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/ico.0b013e3181e2f0f3","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T07:25:49Z","timestamp":1284621949000},"page":"83-90","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of Besifloxacin, Gatifloxacin, and Moxifloxacin Against Strains of Pseudomonas aeruginosa With Different Quinolone Susceptibility Patterns in a Rabbit Model of Keratitis"],"prefix":"10.1097","volume":"30","author":[{"given":"Melissa E","family":"Sanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy C","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin W","family":"Norcross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine K","family":"Hesje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Shafiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E","family":"Marquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210204","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/archopht.1993.01090120087027","article-title":"Incidence of ulcerative keratitis in a defined population from 1950 through 1988.","volume":"111","author":"Erie","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"R2-15-20210204","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archopht.125.5.603","article-title":"Pediatric microbial keratitis in Taiwanese children: a review of hospital cases.","volume":"125","author":"Hsaio","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R3-15-20210204","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.icl.0000234002.88643.d0","article-title":"Microbial keratitis pathogens and antibiotic susceptibilities: a 5-year review of cases at an urban county hospital in north Texas.","volume":"33","author":"Pachigolla","year":"2007","journal-title":"Eye Contact Lens"},{"key":"R4-15-20210204","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjo.2002.011205","article-title":"Distribution and shifting trends of bacterial keratitis in north China (1989-98).","volume":"88","author":"Sun","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R5-15-20210204","first-page":"664","article-title":"Contact lens wear and microbial keratitis.","volume":"100","author":"Ahuja","year":"2002","journal-title":"J Indian Med Assoc"},{"key":"R6-15-20210204","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/0301-4738.29500","article-title":"Ulcerative keratitis associated with contact lens wear.","volume":"55","author":"Bharathi","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"R7-15-20210204","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ico.0000138839.29823.57","article-title":"Trends in contact lens-related corneal ulcers.","volume":"24","author":"Mah-Sadorra","year":"2005","journal-title":"Cornea"},{"key":"R8-15-20210204","first-page":"737","article-title":"Contact lens-related microbial keratitis.","volume":"90","author":"Preechawatmd","year":"2007","journal-title":"J Med Assoc Thai"},{"key":"R9-15-20210204","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/ICL.0b013e318030c997","article-title":"Recent pattern of contact lens-related keratitis in Hong Kong.","volume":"33","author":"Yu","year":"2007","journal-title":"Eye Contact Lens"},{"key":"R10-15-20210204","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.icl.0000179705.23313.7e","article-title":"Microbial keratitis in overnight orthokeratology: review of the first 50 cases.","volume":"31","author":"Watt","year":"2005","journal-title":"Eye Contact Lens"},{"key":"R11-15-20210204","first-page":"144","article-title":"Amniotic membrane transplantation for pseudomonal keratitis with impending perforation.","volume":"25","author":"Chen","year":"2002","journal-title":"Chang Gung Med J"},{"key":"R12-15-20210204","first-page":"112","article-title":"Causes and management of bacterial keratitis in the elderly.","volume":"24","author":"Ormerod","year":"1989","journal-title":"Can J Ophthalmol"},{"key":"R13-15-20210204","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ajo.2007.01.015","article-title":"Therapeutic keratoplasty for advanced suppurative keratitis.","volume":"143","author":"Ti","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R14-15-20210204","first-page":"760","article-title":"Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis.","volume":"94","author":"Tsai","year":"1995","journal-title":"J Formos Med Assoc"},{"key":"R15-15-20210204","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/bjo.87.7.805","article-title":"Microbial keratitis.","volume":"87","author":"Jeng","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R16-15-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/OPX.0b013e3180439c3e","article-title":"Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review.","volume":"84","author":"Willcox","year":"2007","journal-title":"Optom Vis Sci"},{"key":"R17-15-20210204","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0161-6420(96)30668-4","article-title":"Differential care of corneal ulcers in the community based on apparent severity.","volume":"103","author":"McLeod","year":"1996","journal-title":"Ophthalmology"},{"key":"R18-15-20210204","first-page":"175","article-title":"Conrad Berens lecture: the management of infectious keratitis as we approach the 21st century.","volume":"24","author":"Forster","year":"1998","journal-title":"CLAO J"},{"key":"R19-15-20210204","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-200161060-00004","article-title":"Fluoroquinolones: place in ocular therapy.","volume":"61","author":"Smith","year":"2001","journal-title":"Drugs"},{"key":"R20-15-20210204","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-4781(98)00127-4","article-title":"Bacterial topoisomerases, anti-topoisomerases, and antitopoisomerase resistance.","volume":"1400","author":"Hooper","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"R21-15-20210204","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1369-5274(99)00008-9","article-title":"Mechanism of fluoroquinolone action.","volume":"2","author":"Drlica","year":"1999","journal-title":"Curr Opin Microbiol"},{"key":"R22-15-20210204","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.289.7.885","article-title":"Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.","volume":"289","author":"Neuhauser","year":"2003","journal-title":"JAMA"},{"key":"R23-15-20210204","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1086\/514909","article-title":"Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.","volume":"27","author":"Hancock","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R24-15-20210204","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/.61.3.377-392.1997","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones.","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol Mol Biol Rev"},{"key":"R25-15-20210204","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2958.1993.tb00925.x","article-title":"Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine.","volume":"10","author":"Poole","year":"1993","journal-title":"Mol Microbiol"},{"key":"R26-15-20210204","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1128\/JB.175.22.7363-7372.1993","article-title":"Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon.","volume":"175","author":"Poole","year":"1993","journal-title":"J Bacteriol"},{"key":"R27-15-20210204","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2958.1996.281397.x","article-title":"Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa.","volume":"21","author":"Poole","year":"1996","journal-title":"Mol Microbiol"},{"key":"R28-15-20210204","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2958.1997.2281594.x","article-title":"Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa.","volume":"23","author":"Kohler","year":"1997","journal-title":"Mol Microbiol"},{"key":"R29-15-20210204","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1128\/AAC.38.8.1732","article-title":"Role of efflux pump (s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin.","volume":"38","author":"Li","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-15-20210204","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1076\/ceyr.28.5.337.28676","article-title":"Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.","volume":"28","author":"Thibodeaux","year":"2004","journal-title":"Curr Eye Res"},{"key":"R31-15-20210204","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/ICO.0b013e318033a6f2","article-title":"Zymar (gatifloxacin 0.3%) shows excellent gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand white rabbit keratitis model.","volume":"26","author":"Mah","year":"2007","journal-title":"Cornea"},{"key":"R32-15-20210204","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/S0161-6420(01)00724-2","article-title":"An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.","volume":"108","author":"Kowalski","year":"2001","journal-title":"Ophthalmology"},{"key":"R33-15-20210204","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0301-4738.29489","article-title":"Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.","volume":"55","author":"Duggirala","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"R34-15-20210204","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcrs.2005.12.108","article-title":"Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.","volume":"32","author":"Moshirfar","year":"2006","journal-title":"J Cataract Refract Surg"},{"key":"R35-15-20210204","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1128\/AAC.00418-09","article-title":"Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.","volume":"53","author":"Haas","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-15-20210204","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/ICO.0b013e31819e34cb","article-title":"Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.","volume":"28","author":"Sanders","year":"2009","journal-title":"Cornea"},{"key":"R39-15-20210204","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3109\/02713689008997584","article-title":"The role of pneumolysin in ocular infections with Streptococcus pneumoniae.","volume":"9","author":"Johnson","year":"1990","journal-title":"Curr Eye Res"},{"key":"R40-15-20210204","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1073\/pnas.0711767105","article-title":"A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus.","volume":"105","author":"Shelburne","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R41-15-20210204","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archopht.121.9.1229","article-title":"Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis.","volume":"121","author":"Wilhelmus","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R42-15-20210204","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1167\/iovs.09-3933","article-title":"Bacterial susceptibility to topical antimicrobial and clinical outcome in bacterial keratitis.","volume":"51","author":"Kaye","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R43-15-20210204","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1128\/AAC.31.11.1803","article-title":"Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.","volume":"31","author":"Michea-Hamzehpour","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"R44-15-20210204","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1128\/AAC.45.8.2263-2268.2001","article-title":"Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.","volume":"45","author":"Akasaka","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-15-20210204","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1128\/AAC.47.5.1681-1688.2003","article-title":"Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.","volume":"47","author":"Karlowsky","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-15-20210204","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/AAC.44.3.710-712.2000","article-title":"Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.","volume":"44","author":"Jalal","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R47-15-20210204","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijantimicag.2004.11.012","article-title":"Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.","volume":"25","author":"Lee","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R48-15-20210204","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkn528","article-title":"Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.","volume":"63","author":"Cambau","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R49-15-20210204","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/AAC.43.2.410","article-title":"Primary targets of fluoroquinolones in Streptococcus pneumoniae.","volume":"43","author":"Fukuda","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R50-15-20210204","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jac\/45.5.583","article-title":"Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.","volume":"45","author":"Pestova","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"R51-15-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/43.suppl_2.31","article-title":"The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.","volume":"43","author":"Schedletzky","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"R52-15-20210204","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/AAC.42.10.2678","article-title":"Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.","volume":"42","author":"Takei","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R53-15-20210204","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.icl.0000215432.96891.1f","article-title":"Susceptibility testing of clinical isolates of Pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating Pseudomonas ocular infections.","volume":"32","author":"Epstein","year":"2006","journal-title":"Eye Contact Lens"},{"key":"R54-15-20210204","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000085612","article-title":"Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.","volume":"51","author":"Muramatsu","year":"2005","journal-title":"Chemotherapy"},{"key":"R55-15-20210204","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/jac\/dkm398","article-title":"Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes.","volume":"61","author":"Zhang","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R57-15-20210204","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jama.296.8.953","article-title":"Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution.","volume":"296","author":"Chang","year":"2006","journal-title":"JAMA"},{"key":"R58-15-20210204","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clinthera.2009.03.010","article-title":"Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.","volume":"31","author":"Karpecki","year":"2009","journal-title":"Clin Ther"},{"key":"R59-15-20210204","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1185\/03007990902837919","article-title":"Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.","volume":"25","author":"Tepedino","year":"2009","journal-title":"Curr Med Res Opin"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0b013e3181e2f0f3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:05Z","timestamp":1786041185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201101000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3181e2f0f3","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}